Navigation Links
Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

om" target="_new">http://www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Al Khaimah, United Arab Emirates (UAE) (PRWEB) July 23, ... firm Grace Century recently announced that its ... Dr. Jim Vaught , Ph.D. to its growing Advisory ... said, “We are very pleased to have Dr. Vaught ... with the scientific depth and expertise that Provia’s management ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
(Date:7/23/2014)... 2014  AuraSense Therapeutics, the pioneer in developing spherical ... and immunotherapeutic agents, announced today that ... executive leadership team as chief financial officer ... joining AuraSense Therapeutics, Mr. Snyder was Executive ... Cellular Dynamics International Inc., where he was ...
(Date:7/23/2014)... July 23, 2014  Having the right people at ... to accelerating business growth and achieving clinical and operational ... (AHA) Leadership Summit, July 20-22, 2014, in ... hospital executives and healthcare experts discussing how partnerships have ... , President & Chief Executive Officer of Cape Regional ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... ... distribute feedstock for E-Fuel MicroFueler™ , ... Sacramento (Vocus) June 4, 2009 -- California Governor Arnold Schwarzenegger joined ... Corp. unveiled the final production model of the revolutionary E-Fuel MicroFueler, a portable micro-refinery ...
... WEBCAST WEDNESDAY, JUNE 10, 2009 , , SAN ... NBIX ) announced today that Kevin Gorman, President and Chief ... 8th Annual Needham Life Sciences Conference in New York. ... 10, 2009 at 1:30 p.m. Eastern Time (ET)/10:30 a.m. Pacific ...
... , BRAINTREE, Mass., June 4 Haemonetics Corporation (NYSE: ... for the District of Massachusetts has made a ruling in ... January 2009, a jury issued a verdict in favor of ... a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 ...
Cached Biology Technology:GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 2GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 3Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
(Date:7/24/2014)... electric cars ply silent freeways, solar panels blanket rooftops ... earth, from howling winds and from the blazing desert ... is technically and economically feasible to convert California,s all-purpose ... Published in Energy , the plan shows the ... in California that could create tens of thousands of ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... at NJIT this week for an all-day public forum ... Protection Agency (EPA) to dredge toxic sediment from an ... EPA has called the plan, which proposes removing 4.3 ... of the riverbed, one of the largest cleanups in ... and disposed off-site. , "We need to ensure the ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... Michigan State University scientists has shed new light on why ... others, work that could someday lead to better ways of ... The research, led by assistant zoology professor Alexander Shingleton, is ... Library of Science Genetics. In particular, Shingleton is studying ...
... Dallas are examining whether multiple areas of the brain ... new medical interventions against the disabling effects of severe ... professor in UT Dallas, School of Behavioral and Brain ... in the hippocampus, a section of the brain not ...
... release is available in German . ... spread of pathogens. One prerequisite for the release of ... gene variant does not spread uncontrollably, suppressing natural populations. ... in Pln, Germany, have now established that certain mutations ...
Cached Biology News:New research on body parts' sensitivity to environmental changes 2UT Dallas research widens study of brain's role in tinnitus 2Mutants with heterozygote disadvantage can prevent spread of transgenic animals 2Mutants with heterozygote disadvantage can prevent spread of transgenic animals 3
... polyclonal to ThPok ( Abpromise for all ... peptide conjugated to KLH derived from within residues ... (Note: the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Pronase Reagent...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: